AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Citigroup Boosts Zymeworks Price Target to $22, Maintains Buy Rating
ByAinvest
Wednesday, Aug 13, 2025 10:55 am ET1min read
Citigroup analyst Yigal Nochomovitz maintains a Buy rating on Zymeworks (ZYME) with a raised price target of $22.00, a 15.79% increase. The updated analyst outlooks on Zymeworks can be insightful for investors considering positions in the bio-pharmaceutical sector. Zymeworks is a clinical-stage biopharmaceutical company with a clinical candidate, zanidatamab, currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally.
Analysts are bullish on healthcare stocks, with strong buy ratings for Neuren Pharmaceuticals (NURPF), Zymeworks (ZYME), and Celldex (CLDX). Neuren Pharmaceuticals has a strong buy consensus rating with an average price target of $17.35, representing a potential 57.7% upside. Zymeworks has received a moderate buy rating with an average price target of $20.88, which implies a 69.5% upside. Celldex has been given a strong buy rating with an average price target of $55.25, representing a potential 169.0% upside. These ratings reflect analysts' optimism about the future prospects of these healthcare stocks [1].Zymeworks, a clinical-stage biopharmaceutical company, has seen its stock price rise following positive earnings reports and strategic partnerships. Citigroup analyst Yigal Nochomovitz maintains a Buy rating on Zymeworks (ZYME) with a raised price target of $22.00, a 15.79% increase. The updated analyst outlooks on Zymeworks can be insightful for investors considering positions in the bio-pharmaceutical sector. Zymeworks is a clinical-stage biopharmaceutical company with a clinical candidate, zanidatamab, currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally [2].
These ratings suggest that investors should closely monitor the developments of these healthcare stocks, as they are expected to perform well in the coming months and years. However, it is important for investors to conduct their own research and consider their risk tolerance before making any investment decisions.
References:
[1] https://www.ainvest.com/news/healthcare-analysts-bullish-neuren-pharmaceuticals-zymeworks-celldex-2508/
[2] https://seekingalpha.com/news/4482875-zymeworks-signals-expanded-royalty-streams-and-milestone-driven-cash-infusions-through-new
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet